CORE Biomedicine, Inc. Selected to Present at LUMINESCENCE During the 2025 BIO Convention in Boston, MA

Boston, MA –Jun 1, 2025 — CORE Biomedicine, Inc., an innovative biotechnology company advancing transformative approaches in oncology, is honored to announce its acceptance to present at LUMINESCENCE, a key industry showcase within the 2025 BIO Convention. The annual event will take place June 22–25, 2025, in Boston, Massachusetts — bringing together global biotechnology leaders, investors, policymakers, and innovators to explore breakthroughs shaping the future of life sciences. More information on the BIO Convention program can be found here: https://convention.bio.org/program

The BIO Convention is the largest global gathering of the biotechnology community, featuring cutting-edge scientific sessions, high-level plenary speakers, partnering meetings, and showcases like LUMINESCENCE where emerging biotechs pitch to investors, strategic partners, and thought leaders.

LUMINESCENCE is the premier stage at the BIO Convention for emerging and high-impact companies to share their most exciting scientific platforms and clinical strategies with a global audience of industry decision-makers and potential partners. CORE Biomedicine’s selection underscores its position at the forefront of oncology innovation.

CORE Biomedicine’s presentation at LUMINESCENCE will spotlight its innovative platform for identifying first-in-class and best-in-class oncology targets rooted in lineage-driven biology—a strategy designed to deliver transformative benefit to broader patient populations.

For additional details about the 2025 BIO Convention program, agenda, and speakers, please visit: https://convention.bio.org/program

About CORE Biomedicine, Inc.
Founded by the former leadership of H3 Biomedicine, CORE Biomedicine, Inc. is building the next wave of oncology innovation by going beyond precision medicine. CORE’s lineage-based therapeutic platform targets the fundamental biological programs that define cancer cell identity, enabling the discovery of first- and best-in-class medicines with the potential to reach significantly larger patient populations.

Contact

Contact: contact@corebiomedicine.com